Compare JPMorgan Chase & Co (JPM) vs Oscar Health Inc (OSCR) Price & Performance

JPMorgan Chase (JPM) trades at $359.79, up 0.63% today, with a bullish technical signal from moving averages and a consensus analyst price target of $374.18. Recent earnings have shown strength with beats in Q1 and Q2 2026, though Q4 2025 missed expectations. Revenue and net income have grown steadily, with 2025 revenue at $181.85B and net income at $57.05B, though cash flow from operations remains negative. The stock exhibits strong institutional interest and a moderate buy rating from analysts.

The outlook for JPM is positive, supported by robust profitability metrics like an 18.43% ROE and a net income margin of 33.38%. Key risks include geopolitical tensions impacting banking sectors and persistent negative operating cash flows. Upside potential exists if the company meets or exceeds future earnings expectations, with the next catalyst being Q3 2026 results.

OSCR trades at $27.97, up 1.08% today, with a bearish technical signal but strong recent earnings beats in Q1 and Q2 2026. The company reported record profitability and raised its full-year outlook, driven by membership growth and cost controls. Key support lies at $26, with resistance at $28. Revenue surged 70% year-over-year in H1 2026 to $4.9 billion, per PYMNTS on August 6, 2026.

Outlook is positive due to robust growth and margin expansion, but risks include execution challenges and competitive pressures. Analysts have a consensus price target of $32.50, with 27% buy ratings. The stock offers value with a P/S of 0.53, though net income volatility remains a concern.